SEATTLE, Nov. 8, 2017 /PRNewswire/ -- CTI BioPharma
Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that
management will present at the Jefferies 2017 London Healthcare
Conference Wednesday, November 15,
2017 at 12:20 p.m. ET /
5:20 p.m. GMT in London.
The presentation will be webcast live and available for replay
from the Investors section of CTI BioPharma's website at
www.ctibiopharma.com.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on
the acquisition, development and commercialization of novel
targeted therapies covering a spectrum of blood-related cancers
that offer a unique benefit to patients and healthcare providers.
CTI BioPharma has a late-stage development pipeline, including
pacritinib for the treatment of patients with myelofibrosis. CTI
BioPharma is headquartered in Seattle,
Washington. For additional information and to sign up for
email alerts and get RSS feeds, please visit
www.ctibiopharma.com.
CTI BioPharma Contacts:
Ed Bell
+1 206-272-4345
ebell@ctibiopharma.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jefferies-2017-london-healthcare-conference-300551414.html
SOURCE CTI BioPharma Corp.